Axoft Announces Commercialization of Fleuron, Covered by an Exclusive License Agreement with Stanford University

Clinical translation of ultrasoft Fleuron™ probes for stable, high-density, and bidirectional brain interfaces

Axoft completes first human cases with ultrasoft BCI